• SPX
  • $5,626.02
  • 0.54 %
  • $30.26
  • DJI
  • $41,393.78
  • 0.72 %
  • $297.01
  • N225
  • $36,581.76
  • -0.68 %
  • -$251.51
  • FTSE
  • $8,273.09
  • 0.39 %
  • $32.12
  • IXIC
  • $17,683.98
  • 0.65 %
  • $114.30
Fusion Pharmaceuticals Inc. (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals Inc. (FUSN) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$21.48
Day's range
$21.58
50-day range
$0
Day's range
$21.6
  • Country: CA
  • ISIN: CA36118A1003
52 wk range
$2.31
Day's range
$21.6
  • CEO: Dr. John F. Valliant Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.39
  • Piotroski Score 3.00
  • Grade Neutral
  • Symbol (FUSN)
  • Company Fusion Pharmaceuticals Inc.
  • Price $21.55
  • Changes Percentage (0.14%)
  • Change $0.03
  • Day Low $21.48
  • Day High $21.58
  • Year High $21.60

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $17.00
  • High Stock Price Target $21.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.40
  • Trailing P/E Ratio -15.39
  • Forward P/E Ratio -15.39
  • P/E Growth -15.39
  • Net Income $-94,897,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.